11/15
02:08 pm
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Guggenheim from $24.00 to $28.00. They now have a "buy" rating on the stock.
Medium
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Guggenheim from $24.00 to $28.00. They now have a "buy" rating on the stock.
11/12
07:00 am
cnta
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Low
Report
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
11/4
07:30 am
cnta
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
9/26
06:00 am
cnta
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Low
Report
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
9/19
07:05 pm
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $26.00 price target on the stock, up previously from $11.00.
Low
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $26.00 price target on the stock, up previously from $11.00.
9/19
07:58 am
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $33.00 price target on the stock.
Low
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $33.00 price target on the stock.
9/16
09:13 am
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $20.00 to $35.00. They now have an "outperform" rating on the stock.
Low
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $20.00 to $35.00. They now have an "outperform" rating on the stock.
9/12
10:41 pm
cnta
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares [Yahoo! Finance]
High
Report
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares [Yahoo! Finance]
9/12
10:34 pm
cnta
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
9/11
04:04 pm
cnta
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
9/11
01:29 pm
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Guggenheim from $20.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Guggenheim from $20.00 to $24.00. They now have a "buy" rating on the stock.
9/11
12:19 pm
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Jefferies Financial Group Inc. from $13.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at Jefferies Financial Group Inc. from $13.00 to $19.00. They now have a "buy" rating on the stock.
9/10
07:00 am
cnta
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Medium
Report
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
9/9
08:45 am
cnta
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $15.00 to $20.00. They now have an "outperform" rating on the stock.
Low
Report
Centessa Pharmaceuticals plc (NASDAQ: CNTA) had its price target raised by analysts at BMO Capital Markets from $15.00 to $20.00. They now have an "outperform" rating on the stock.